A Phase II Study (TACTI-002) in First-Line Metastatic Non–small Cell Lung Carcinoma Investigating Eftilagimod Alpha (soluble LAG-3 Protein) and Pembrolizumab: Updated Results from a PD-L1 Unselected Population.
JOURNAL OF CLINICAL ONCOLOGY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要